Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus

Pediatric Diabetes

Volumn 12, Issue 7, 2011, Pages 632-641

  Thalange, Nandu ^a   Bereket, Abdullah ^b   Larsen, Jens ^c   Hiort, Line Conradsen ^c   Peterkova, Valentina ^d  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NOVO NORDISK A S   (Denmark)

^d RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

Author keywords

AE; BMI; DCCT; Detemir; FPG; GIR; HbA1c; HPLC; IAsp; IDet; IVRS; NPG; NPH; Paediatrics; PG; Randomised clinical trial; SAE; Safety; SMPG; T1DM

Indexed keywords

HEMOGLOBIN A1C; HUMAN ISOPHANE INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ARTICLE; CHILD; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNCONSCIOUSNESS; WEIGHT GAIN;

BODY WEIGHT; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE;

EID: 80055064859     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2010.00750.x     Document Type: Article

References (31)

1. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993: 341: 1306-1309.
2. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996: 45: 1289-1298.
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New Engl J Med 1993: 329: 304-309.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993: 329: 977-986.
5. Amin R, Widmer B, Prevost AT et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008: 336: 697-701.
6. De Beaufort CE, Bruining GJ, Home PD, Houtzagers CM, Van SR. Overnight metabolic profiles in very young insulin-dependent diabetic children. Eur J Pediatr 1986: 145: 73-76.
7. Ludvigsson J, Bolli GB. Intensive insulin treatment in diabetic children. Diabetes Nutr Metab 2001: 14: 292-304.
8. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004: 21: 1498-1504.
9. Danne T, Datz N, Endahl L et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008: 9: 554-560.
10. Danne T, Lüpke K, Walte K, Von SW, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003: 26: 3087-3092.
11. Heise T, Nosek L, Rønn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-1620.
12. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999: 354: 1604-1607.
13. De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005: 7: 73-82.
14. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004: 47: 622-629.
15. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004: 27: 1081-1087.
16. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004: 26: 724-736.
17. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007: 24: 27-34.
18. ®) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005: 70: 1-7.
19. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003: 5: 801-806.
20. Cogen F, Henderson C, Guttmann-Baumann I. Basal/bolus regimen using insulin glargine and rapid-acting insulin analogs in children under 6 years of age: a clinical experience in a large urban practice. Diabetes 2004: 53 (Suppl. 2): A420.
21. Thalange N, Bereket A, Larsen J, Conradsen Hiort L, Peterkove V. Comparison of insulin detemir and NPH insulin in children and adolescents (2-16 years) with T1DM: a 52-week randomized clinical trial. Diabetologia 2009: 52 (Suppl.1): S387.
22. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), Step 4. 1996.
23. WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human patients, 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 and last amended with note of clarification on paragraph 29 by the WMA General Assembly 2002 Washington.
24. ISPAD Guidelines. (available from).
25. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2008: 9: 165-174.
26. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998: 17: 407-429.
27. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008: 25: 442-449.
28. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003: 26: 590-596.
29. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986: 315: 215-219.
30. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993: 42: 1700-1707.
31. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002: 45: 937-948.